A release on Durbin's website says that the ad in question appears to exploit a loophole "regarding promotions of compounded drugs by telehealth companies."
The senators said they believe the FDA may have the authority to take enforcement actions against marketing that could mislead patients, and they plan to introduce new legislation to address regulatory loopholes.